TY - JOUR
T1 - Impact of anti-HER2 therapy alone and with weekly paclitaxel on the ovarian reserve of young women with HER2-positive breast cancer
T2 - Biomarker analysis of the NeoALTTO trial
AU - Lambertini, Matteo
AU - Ceppi, Marcello
AU - Anderson, Richard A
AU - Cameron, David A
AU - Bruzzone, Marco
AU - Franzoi, Maria Alice
AU - Massarotti, Claudia
AU - El-Abed, Sarra
AU - Wang, Yingbo
AU - Lecocq, Christophe
AU - Nuciforo, Paolo
AU - Rolyance, Rebecca
AU - Pusztai, Lajos
AU - Sohn, Joohyuk
AU - Ligato, Jacopo
AU - Latocca, Maria Maddalena
AU - Arecco, Luca
AU - Pistilli, Barbara
AU - Ruddy, Kathryn J
AU - Ballestrero, Alberto
AU - Del Mastro, Lucia
AU - Peccatori, Fedro
AU - Partridge, Ann H.
AU - Saura , Cristina
AU - Untch, Michael
AU - Piccart, Martine
AU - Di Cosimo, Serena
AU - de Azambuja, Evandro
AU - Demeestere, Isabelle
N1 - Funding Information:
The NeoALTTO trial received financial support from GlaxoSmithKline (until January 2015) and Novartis Pharma AG (as of January 2015). Research reported in this publication was supported by the Italian Association for Cancer Research under award number MFAG 2020 ID 246989 (M. Lambertini) and the Italian Ministry of Health (5x1000 funds 2017; M. Lambertini).
Publisher Copyright:
© 2023 Harborside Press. All rights reserved.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Background: The potential gonadotoxicity of anti-HER2 agents remains largely unknown, and limited, conflicting evidence exists for taxanes. Antimüllerian hormone (AMH) is an established biomarker of ovarian reserve that may aid in quantifying anticancer treatment–induced gonadotoxicity. Patients and Methods: The present biomarker analysis of the randomized phase III neoadjuvant NeoALTTO trial included premenopausal women aged ≤45 years at diagnosis of HER2-positive early breast cancer with available frozen serum samples at baseline (ie, before anticancer treatments), at week 2 (ie, the “biological window” of anti-HER2 therapy alone), and/or at the time of surgery (ie, after completing paclitaxel + anti-HER2 therapy, before starting adjuvant chemotherapy). Results: The present analysis included 130 patients with a median age of 38 years (interquartile ratio [IQR], age 33–42 years). AMH values at the 3 time points differed significantly (P
AB - Background: The potential gonadotoxicity of anti-HER2 agents remains largely unknown, and limited, conflicting evidence exists for taxanes. Antimüllerian hormone (AMH) is an established biomarker of ovarian reserve that may aid in quantifying anticancer treatment–induced gonadotoxicity. Patients and Methods: The present biomarker analysis of the randomized phase III neoadjuvant NeoALTTO trial included premenopausal women aged ≤45 years at diagnosis of HER2-positive early breast cancer with available frozen serum samples at baseline (ie, before anticancer treatments), at week 2 (ie, the “biological window” of anti-HER2 therapy alone), and/or at the time of surgery (ie, after completing paclitaxel + anti-HER2 therapy, before starting adjuvant chemotherapy). Results: The present analysis included 130 patients with a median age of 38 years (interquartile ratio [IQR], age 33–42 years). AMH values at the 3 time points differed significantly (P
U2 - 10.6004/jnccn.2022.7065
DO - 10.6004/jnccn.2022.7065
M3 - Article
SN - 1540-1405
VL - 21
SP - 33
EP - 41
JO - Journal of the National Comprehensive Cancer Network
JF - Journal of the National Comprehensive Cancer Network
IS - 1
ER -